David O'Day
Well-Known Member
Not sure its a huge issue. Better to have decent quality control than push on with vaccines that may not work or have side effects, or as in the case of the UoQ one have a knock on effect in public health due to triggering HIV false positives. We're way ahead of where we were expecting to be in terms of vaccines, to expect every vaccine in development to fly through testing with no issues isn't realistic.
In the case of the UoQ vaccine it won't actually mean there is less doses in circulation as their manufacturer, CSL, will now produce 20 million doses of the Astra vaccine for use in Australia. And GSK are still expecting to be ready to manufacture in 2021.
You need as many different types of vaccine in circulation as possible. What happens if there is mutation and suddenly the current vaccineds are less effective or don't work?
GSK are hopeful but they really don't know what will happen as they have had to start phase 2 again.